Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products

Stock Track

06/23

HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.

The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.

Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1169390619"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169390619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169390619?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169390619","market":"sg","top_or_hot":-1,"title":"Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products","media":"Stock Track","content":"<p>HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.</p><p>The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.</p><p>Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HJ SCIENCE-B Plummets 5.01% Intraday as Clinical-Stage Biotech Debuts with No Revenue or Approved Products\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-23 09:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.</p><p>The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.</p><p>Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06132","symbol_name":"華健未來-B","start_time":0,"source_url":"","article_id":"1169390619","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169390619","pubTimestamp":1782178468,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.The company is a clinical-stage biotechnology firm with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06132":"华健未来-B"},"translate_title":"个股追踪|HJ SCIENCE-B盘中暴跌5.01%，临床阶段生物技术首次亮相无营收或获批产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06132":1},"content_text":"HJ SCIENCE-B (06132) saw its stock price plummet 5.01% during intraday trading on Tuesday, shortly after its debut on the Hong Kong exchange.The company is a clinical-stage biotechnology firm with three core products—HJ787, HJ178, and HJ891—all classified as Category 1 innovative drugs but still awaiting regulatory approval. According to its prospectus, HJ SCIENCE-B has not yet received approval for the commercial sale of any products and has generated no revenue from product sales to date.Investor sentiment appeared cautious as the market assessed the company's early-stage development status and lack of commercial track record, despite its integrated drug development platform covering everything from drug design to clinical studies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}